Lb Pharmaceuticals Inc (LBRX) · Sep 15, 2026 · Exec change

LB Pharmaceuticals names seasoned CNS CMO as LB-102 pipeline enters late-stage execution

CMO appointment — Former Centessa clinical-development head; 200,000-share inducement option

LB Pharmaceuticals hires a clinical-development veteran to lead its expanding LB-102 program, adding execution depth but no new clinical data.

LB Pharmaceuticals is a late-stage neuromedicine company pushing its lead candidate LB-102 through a pivotal Phase 3 schizophrenia trial and a Phase 2 bipolar-depression trial, while expanding toward additional psychiatric indications. The appointment strengthens the execution bench. Susan Kozauer brings recent senior clinical-development experience at Centessa and earlier experience at Intra-Cellular Therapies, which is directly relevant as LB-102 moves through multiple late-stage programs. 〔0〕

This is an operational upgrade, not a pipeline inflection. The filing adds no efficacy, safety, regulatory, enrollment, or timing change; it mainly puts an experienced psychiatric-development leader in place to manage a program whose value still depends on future trial execution. 〔1〕

The package is meaningful but not destabilizing for a clinical-stage company. Kozauer receives a $515,000 base salary, a 40% target bonus, a $150,000 sign-on payment, and an option for 200,000 shares that vests over four years. 〔2〕 The equity award aligns her with longer-term development milestones, while the severance and change-of-control protections are standard executive-retention provisions rather than evidence of a strategic transaction.

Bottom line: This is a credible management addition at an important execution point, but it does not change the clinical risk or the timing of LB-102’s value drivers. The business story improves modestly; the next meaningful proof remains trial progress, not the hiring itself.

What to watch next

NOVA-2 schizophrenia topline data, first half 2027

Original filing on SEC EDGAR

More Lb Pharmaceuticals Inc news

LB Pharmaceuticals names seasoned CNS CMO as LB-102 pipeline enters late-stage execution | LBRX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.